<DOC>
	<DOCNO>NCT00198978</DOCNO>
	<brief_summary>The study evaluate efficacy tolerability dose-reduced chemotherapy treatment elderly patient acute lymphoblastic leukemia . In patient expression CD20 leukemic cell efficacy tolerability additional application Rituximab together chemotherapy evaluate .</brief_summary>
	<brief_title>German Multicenter Trial Treatment Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Diagnosis acute lymphoblastic leukemia ( pro B , pre B , cALL TALL ) , prove morphology immunophenotyping Age &gt; 55 yr ( upper age limit ) Written informed consent Severe leukemia associate complication , controllable therapy onset e.g . life threaten infection sepsis , pneumonia , hypoxia , shock , life threaten bleed ) Severe comorbidity e.g . decompensated renal failure cause leukemia Creatinine &gt; 2x ULN heart failure ( NYHA II/IV ) , instable Angina , significant coronary stenosis hepatic insufficiency e.g . liver cirrhosis chronic active hepatitis bilirubin &gt; 1,5 x ULN and/or ASA , ALA , AP &gt; 2,5 ULN decompensated metabolic disturbance ( e.g . controllable diabetes ) severe obstructive restrictive pulmonary disease hypoxaemia Severe psychiatric illness circumstance may compromise cooperation patient Active second neoplasia HIV infection Severely reduce general condition Cytostatic pretreatment ALL Chemotherapy treatment malignancy last 5 year Participation clinical trial interfere study therapy</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>ALL</keyword>
	<keyword>Treatment</keyword>
	<keyword>Elderly</keyword>
	<keyword>De novo</keyword>
</DOC>